Macquarie Group Ltd. Has $854,000 Holdings in Sucampo Pharmaceuticals, Inc. (SCMP)

Macquarie Group Ltd. grew its stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 7.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,402 shares of the biopharmaceutical company’s stock after buying an additional 5,002 shares during the quarter. Macquarie Group Ltd. owned approximately 0.16% of Sucampo Pharmaceuticals worth $854,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. HPM Partners LLC purchased a new stake in Sucampo Pharmaceuticals in the second quarter worth about $1,307,000. Louisiana State Employees Retirement System increased its position in Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 100 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new stake in Sucampo Pharmaceuticals in the third quarter worth about $127,000. JPMorgan Chase & Co. purchased a new stake in Sucampo Pharmaceuticals in the second quarter worth about $117,000. Finally, Aperio Group LLC purchased a new stake in Sucampo Pharmaceuticals in the third quarter worth about $137,000. Institutional investors and hedge funds own 65.31% of the company’s stock.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at $16.00 on Monday. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals, Inc. has a 1 year low of $9.30 and a 1 year high of $17.70. The stock has a market capitalization of $746.19, a PE ratio of 10.96, a P/E/G ratio of 4.76 and a beta of 1.47.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. During the same quarter last year, the business posted $0.30 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. analysts forecast that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current fiscal year.

SCMP has been the subject of a number of analyst reports. initiated coverage on Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 price target for the company. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. UBS reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Mizuho reiterated a “hold” rating and set a $12.00 target price on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 1st. Finally, Maxim Group reiterated a “buy” rating and set a $23.00 target price on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $16.60.

TRADEMARK VIOLATION NOTICE: “Macquarie Group Ltd. Has $854,000 Holdings in Sucampo Pharmaceuticals, Inc. (SCMP)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://sportsperspectives.com/2017/12/11/macquarie-group-ltd-has-854000-holdings-in-sucampo-pharmaceuticals-inc-scmp.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply